Overview

ALK21-003EXT: An Extension of Study ALK21-003 (NCT01218958) to Test the Long-term Safety of Medisorb® Naltrexone (VIVITROL®)

Status:
Completed

Trial end date:
2004-09-01

Target enrollment:

Participant gender:

Summary

This was a Phase 3 multicenter extension of Alkermes' Study ALK21-003 (NCT01218958 [the base study]) that evaluated the safety of Medisorb® naltrexone (VIVITROL®) administered every 4 weeks for 48 weeks (13 injections) in alcohol-dependent adults who had completed Study ALK21-003.

Phase:

Phase 3

Details

Lead Sponsor:

Alkermes, Inc.

Treatments:

Naltrexone